Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRDM9S)

Drug Name
SCH-602539 Drug Info
Synonyms
SCH-602539; UNII-7467O90MW3; CHEMBL1270738; 7467O90MW3; SCH602539; 618385-42-5; SCHEMBL8058894; BDBM50329618; Carbamic acid, N-((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)furan-6-yl)-, ethyl ester; Ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(2,3'-bipyridin-6'-yl)vinyl)-1-methyl-3-oxododecahydronaphtho(2,3-C)furan-6-yl}carbamate; Carbamic acid, ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)fura
Indication
Disease Entry ICD 11 Status REF
Arteriosclerosis BD40 Investigative [1]
Cross-matching ID
PubChem CID
16214871
CAS Number
CAS 618385-42-5
TTD Drug ID
DMRDM9S

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Proteinase activated receptor 1 (F2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorapaxar DMA16BR Myocardial infarction BA41-BA43 Approved [2]
E5555 DMQERC6 Acute coronary syndrome BA41 Phase 2 [3]
PZ-128 DMU5H3A Peripheral arterial occlusive disorder BD4Z Phase 2 [4]
RWJ-58259 DMYXD6A Artery stenosis BD52 Terminated [5]
FR-171113 DMIQB9E Thrombosis DB61-GB90 Terminated [6]
RWJ-56110 DME07AN Discovery agent N.A. Investigative [7]
SCH-205831 DM584T6 Thrombosis DB61-GB90 Investigative [8]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proteinase activated receptor 1 (F2R) TTL935N PAR1_HUMAN Antagonist [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 347).
2 In Process Citation. Pharm Unserer Zeit. 2009;38(4):320-8.
3 Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011 May 3;123(17):1843-53.
4 PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2990-3003.
5 RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev. 2003 Winter;21(4):313-26.
6 In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur J Pharmacol. 1999 Nov 19;384(2-3):197-202.
7 Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12257-62.
8 Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4509-13.